Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma
LUGANO-MADRID, 11 September, 2017 - Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at...





